Ascendis Pharma A/S 6-K Filing
Ticker: ASND · Form: 6-K · Filed: Apr 7, 2026 · CIK: 0001612042
Sentiment: neutral
Filing Stats: 796 words · 3 min read · ~3 pages · Grade level 20 · Accepted 2026-04-07 06:01:25
Filing Documents
- d121667d6k.htm (6-K) — 14KB
- 0001193125-26-144463.txt ( ) — 15KB
Forward-Looking Statements
Forward-Looking Statements This report contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this report regarding Ascendis' future operations, plans and objectives of management are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Examples of such statements include, but are not limited to, statements relating to the anticipated timing of the orphan drug exclusivity granted to YUVIWEL. Ascendis may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Ascendis makes, including, without limitation: dependence on third-party manufacturers, distributors, and service providers for Ascendis' products and product candidates; risks related to regulatory review and approval, including the possibility of delays, requests for additional data or analyses, restrictions or limitations on use, approval with labeling that is more limited than expected, or failure to obtain approval in the United States, European Union, or other jurisdictions; clinical development risks, including that results from ongoing or future trials may not confirm earlier data; unforeseen safety or efficacy findings in development programs or on-market products; manufacturing, supply chain, quality, or logistics issues that could delay development or commercialization; unforeseen expenses related to commercialization of any approved Ascendis products;
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Ascendis Pharma A/S Date: April 6, 2026 By: /s/ Michael Wolff Jensen Michael Wolff Jensen Executive Vice President, Chief Legal Officer